2型糖尿病合并不同非酒精性脂肪性肝病状态下SGLT-2i与GLP-1RA治疗的结局
这项基于韩国全国人群的回顾性活性对照新用药者队列研究,将启动SGLT-2i或GLP-1RA的2型糖尿病患者与启动DPP-4i者按1:1倾向评分匹配。SGLT-2i队列140438例,与DPP-4i相比MACE风险降低(HR 0.78,95%CI 0.71-0.85)、HHF风险降低(HR 0.62,95%CI 0.48-0.81)。GLP-1RA队列34886例,MACE风险降低(HR 0.49,95%CI 0.39-0.62),HHF结果无统计学意义(HR 0.64,95%CI 0.39-1.07)。按NAFLD状态分层结果一致。
要点
- SGLT-2i vs DPP-4i:MACE风险降低(HR 0.78,95%CI 0.71-0.85),HHF风险降低(HR 0.62,95%CI 0.48-0.81)。
- GLP-1RA vs DPP-4i:MACE风险降低(HR 0.49,95%CI 0.39-0.62),HHF结果无统计学意义(HR 0.64,95%CI 0.39-1.07)。
- SGLT-2i合并NAFLD者MACE HR 0.73(95%CI 0.62-0.86),无NAFLD者HR 0.81(95%CI 0.72-0.91)。
- GLP-1RA合并NAFLD者MACE HR 0.49(95%CI 0.32-0.77),无NAFLD者HR 0.49(95%CI 0.37-0.65)。
- SGLT-2i合并NAFLD者HHF HR 0.76(95%CI 0.49-1.17),无NAFLD者HR 0.56(95%CI 0.40-0.78)。
适用人群与场景
- 年龄40岁及以上、启动SGLT-2i或GLP-1RA的2型糖尿病患者,按有无NAFLD分层,并与启动DPP-4i者倾向评分匹配。
- 研究基于韩国2013年1月至2020年12月的全国人群数据。
研究设计与关键结果
- 研究类型:回顾性、基于人群的全国性队列研究,采用活性对照新用药者设计;数据来源韩国2013年1月至2020年12月,数据分析2022年10月至2023年3月。
- SGLT-2i vs DPP-4i队列经1:1倾向评分匹配后140438例(平均[SD]年龄57.5[10.3]岁;男性79633例[56.7%])。
- GLP-1RA vs DPP-4i队列经1:1倾向评分匹配后34886例(平均[SD]年龄59.5[10.5]岁;男性17894例[51.3%])。
- SGLT-2i vs DPP-4i:MACE HR 0.78(95%CI 0.71-0.85),HHF HR 0.62(95%CI 0.48-0.81)。
- GLP-1RA vs DPP-4i:MACE HR 0.49(95%CI 0.39-0.62),HHF HR 0.64(95%CI 0.39-1.07),无统计学意义。
- SGLT-2i按NAFLD分层:MACE合并NAFLD HR 0.73(95%CI 0.62-0.86),无NAFLD HR 0.81(95%CI 0.72-0.91);HHF合并NAFLD HR 0.76(95%CI 0.49-1.17),无NAFLD HR 0.56(95%CI 0.40-0.78)。
- GLP-1RA按NAFLD分层:MACE合并NAFLD HR 0.49(95%CI 0.32-0.77),无NAFLD HR 0.49(95%CI 0.37-0.65);HHF合并NAFLD HR 0.82(95%CI 0.38-1.76),无NAFLD HR 0.54(95%CI 0.27-1.06)。
证据类型、等级与局限
- 证据类型:回顾性、基于人群的全国性队列研究(活性对照新用药者设计)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,在2型糖尿病患者中,无论基线NAFLD状态如何,SGLT-2i治疗与MACE和HHF风险降低相关,GLP-1RA治疗与MACE风险降低相关。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Nonalcoholic fatty liver disease (NAFLD) is a cardiovascular risk factor, but whether sodium-glucose cotransporter-2 inhibitors (SGLT-2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) are associated with reduced cardiovascular risk in patients with type 2 diabetes (T2D) and concomitant NAFLD remains uncertain.
OBJECTIVE: To investigate the outcomes of SGLT-2i and GLP-1RA therapy among patients with T2D varied by the presence or absence of NAFLD.
DESIGN, SETTING, AND PARTICIPANTS: This retrospective, population-based, nationwide cohort study used an active-comparator new-user design. Two distinct new-user active-comparator cohorts of patients aged 40 years and older who initiated SGLT-2i or GLP-1RA were propensity score matched to patients who initiated dipeptidyl peptidase-4 inhibitors (DPP-4i). The study was conducted in South Korea from January 2013 to December 2020, and data analysis was conducted from October 2022 to March 2023.
MAIN OUTCOMES AND MEASURES: The main outcomes were (1) major adverse cardiovascular events (MACE), a composite end point of hospitalization for myocardial infarction, hospitalization for stroke, and cardiovascular death, and (2) hospitalization for heart failure (HHF). Cox proportional hazards models were used to estimate hazard ratios (HRs). The Wald test was applied to assess heterogeneity by NAFLD.
RESULTS: After 1:1 propensity score matching, 140 438 patients were retrieved in the first cohort (SGLT-2i vs DPP-4i; mean [SD] age, 57.5 [10.3] years; 79 633 [56.7%] male) and 34 886 patients were identified in the second cohort (GLP-1RA vs DPP-4i; mean [SD] age, 59.5 [10.5] years; 17 894 [51.3%] male). Compared with DPP-4i, SGLT-2i therapy was associated with a lower risk of MACE (HR, 0.78 [95% CI, 0.71-0.85]) and HHF (HR, 0.62 [95% CI, 0.48-0.81]). GLP-1RA therapy was associated with a decreased risk of MACE (HR, 0.49 [95% CI, 0.39-0.62]) but had statistically nonsignificant findings regarding HHF (HR, 0.64 [95% CI, 0.39-1.07]). Stratified analysis by NAFLD status yielded consistent results for SGLT-2i (MACE with NAFLD: HR, 0.73 [95% CI, 0.62-0.86]; without NAFLD: HR, 0.81 [95% CI, 0.72-0.91]; HHF with NAFLD: HR, 0.76 [95% CI, 0.49-1.17]; without NAFLD: HR, 0.56 [95% CI, 0.40-0.78]) and for GLP-1RA (MACE with NAFLD: HR, 0.49 [95% CI, 0.32-0.77]; without NAFLD: HR, 0.49 [95% CI, 0.37-0.65]; HHF with NAFLD: HR, 0.82 [95% CI, 0.38-1.76]; without NAFLD: HR, 0.54 [95% CI, 0.27-1.06]).
CONCLUSIONS AND RELEVANCE: In this population-based cohort study, SGLT-2i therapy was associated with a decreased risk of MACE and HHF, while GLP-1RA therapy was associated with a decreased risk of MACE among patients with T2D, irrespective of baseline NAFLD status.
参考来源
- Bea S, Jeong HE, Filion KB, et al. Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status. JAMA Netw Open. 2023. PMID: 38153732. doi:10.1001/jamanetworkopen.2023.49856
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。